2-(1-((2-(5-fluoro-1H-indol-4-yl)-4-morpholinopyrido[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-yl)propan-2-ol

ID: ALA2152768

Chembl Id: CHEMBL2152768

Cas Number: 1332075-63-4

PubChem CID: 53378051

Max Phase: Preclinical

Molecular Formula: C28H33FN6O2

Molecular Weight: 504.61

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1

Standard InChI:  InChI=1S/C28H33FN6O2/c1-28(2,36)18-8-11-34(12-9-18)17-19-3-5-23-25(31-19)27(35-13-15-37-16-14-35)33-26(32-23)24-20-7-10-30-22(20)6-4-21(24)29/h3-7,10,18,30,36H,8-9,11-17H2,1-2H3

Standard InChI Key:  ONEJEIKQLAZPNN-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA2152768

   2-(1-{[2-(5-Fluoro-1h-Indol-4-Yl)-4-(Morpholin-4-Yl)pyrido[3,2-D]pyrimidin-6-Yl]methyl}piperidin-4-Yl)propan-2-Ol

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 504.61

Molecular Weight (Monoisotopic): 504.2649

AlogP: 4.13

#Rotatable Bonds: 5

Polar Surface Area: 90.40

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: ┄

CX Basic pKa: 7.89

CX LogP: 4.17

CX LogD: 3.56

Aromatic Rings: 4

Heavy Atoms: 37

QED Weighted: 0.42

Np Likeness Score: -0.93

References

1. Sutherlin DP, Baker S, Bisconte A, Blaney PM, Brown A, Chan BK, Chantry D, Castanedo G, DePledge P, Goldsmith P, Goldstein DM, Hancox T, Kaur J, Knowles D, Kondru R, Lesnick J, Lucas MC, Lewis C, Murray J, Nadin AJ, Nonomiya J, Pang J, Pegg N, Price S, Reif K, Safina BS, Salphati L, Staben S, Seward EM, Shuttleworth S, Sohal S, Sweeney ZK, Ultsch M, Waszkowycz B, Wei B..  (2012)  Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf.,  22  (13): [PMID:22672799] [10.1016/j.bmcl.2012.05.027]

2. Cushing TD, Metz DP, Whittington DA, McGee LR..  (2012)  PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases.,  55  (20): [PMID:22924688] [10.1021/jm300847w]

3. Andrs M, Korabecny J, Jun D, Hodny Z, Bartek J, Kuca K..  (2015)  Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring.,  58  (1): [PMID:25387153] [10.1021/jm501026z]

4. Schwehm C, Kellam B, Garces AE, Hill SJ, Kindon ND, Bradshaw TD, Li J, Macdonald SJ, Rowedder JE, Stoddart LA, Stocks MJ..  (2017)  Design and Elaboration of a Tractable Tricyclic Scaffold To Synthesize Druglike Inhibitors of Dipeptidyl Peptidase-4 (DPP-4), Antagonists of the C-C Chemokine Receptor Type 5 (CCR5), and Highly Potent and Selective Phosphoinositol-3 Kinase δ (PI3Kδ) Inhibitors.,  60  (4): [PMID:28128944] [10.1021/acs.jmedchem.6b01801]

Source

Source(1):

• Scientific Literature